A reversible SRC-relayed COX2-inflammatory program drives therapeutic resistance in BRAF(V600E) colorectal tumors

被引：0

作者：

Atreya, Chloe E. ^{[1
]}

Ruiz-Saenz, Ana ^{[1
]}

Wang, Changjun ^{[1
]}

Pan, Bo ^{[1
]}

Dreyer, Courtney A. ^{[1
]}

Brunen, Diede ^{[2
]}

Prahallad, Anirudh ^{[2
]}

Spassov, Danislav ^{[1
]}

Steffen, Dana J. ^{[3
]}

Hann, Byron C. ^{[1
]}

VandenBerg, Scott R. ^{[1
]}

Gutkind, Silvio ^{[3
]}

Moasser, Mark M. ^{[1
]}

van't Veer, Laura J. ^{[1
]}

Coppe, Jean-Philippe ^{[1
]}

机构：

[1] Univ Calif San Francisco, San Francisco, CA 94143 USA

[2] Netherlands Canc Inst, Amsterdam, Netherlands

[3] Univ Calif San Diego, San Diego, CA 92103 USA

来源：

MOLECULAR CANCER THERAPEUTICS | 2019年 / 18卷 / 12期

关键词：

D O I：

10.1158/1535-7163.TARG-19-B023

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

B023

引用

页数：3

共 35 条

[1] A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAFV600E colorectal tumors
Ana Ruiz-Saenz
Chloe E. Atreya
Changjun Wang
Bo Pan
Courtney A. Dreyer
Diede Brunen
Anirudh Prahallad
Denise P. Muñoz
Dana J. Ramms
Valeria Burghi
Danislav S. Spassov
Eleanor Fewings
Yeonjoo C. Hwang
Cynthia Cowdrey
Christina Moelders
Cecilia Schwarzer
Denise M. Wolf
Byron Hann
Scott R. VandenBerg
Kevan Shokat
Mark M. Moasser
René Bernards
J. Silvio Gutkind
Laura J. van ‘t Veer
Jean-Philippe Coppé
Nature Cancer, 2023, 4 : 240 - 256
[2] A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAFV600E colorectal tumors
Ruiz-Saenz, Ana
Atreya, Chloe E.
Wang, Changjun
Pan, Bo
Dreyer, Courtney A.
Brunen, Diede
Prahallad, Anirudh
Munoz, Denise P.
Ramms, Dana J.
Burghi, Valeria
Spassov, Danislav S.
Fewings, Eleanor
Hwang, Yeonjoo C.
Cowdrey, Cynthia
Moelders, Christina
Schwarzer, Cecilia
Wolf, Denise M.
Hann, Byron
VandenBerg, Scott R.
Shokat, Kevan
Moasser, Mark M.
Bernards, Rene
Gutkind, J. Silvio
van 't Veer, Laura J.
Coppe, Jean-Philippe
NATURE CANCER, 2023, 4 (02) : 240 - +
[3] Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
Sun, Chong
Wang, Liqin
Huang, Sidong
Heynen, Guus J. J. E.
Prahallad, Anirudh
Robert, Caroline
Haanen, John
Blank, Christian
Wesseling, Jelle
Willems, Stefan M.
Zecchin, Davide
Hobor, Sebastijan
Bajpe, Prashanth K.
Lieftink, Cor
Mateus, Christina
Vagner, Stephan
Grernrum, Wipawadee
Hofland, Ingrid
Schlicker, Andreas
Wessels, Lodewyk F. A.
Beijersbergen, Roderick L.
Bardelli, Alberto
Di Nicolantonio, Federica
Eggermont, Alexander M. M.
Bernards, Rene
NATURE, 2014, 508 (7494) : 118 - +
[4] Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
Chong Sun
Liqin Wang
Sidong Huang
Guus J. J. E. Heynen
Anirudh Prahallad
Caroline Robert
John Haanen
Christian Blank
Jelle Wesseling
Stefan M. Willems
Davide Zecchin
Sebastijan Hobor
Prashanth K. Bajpe
Cor Lieftink
Christina Mateus
Stephan Vagner
Wipawadee Grernrum
Ingrid Hofland
Andreas Schlicker
Lodewyk F. A. Wessels
Roderick L. Beijersbergen
Alberto Bardelli
Federica Di Nicolantonio
Alexander M. M. Eggermont
Rene Bernards
Nature, 2014, 508 : 118 - 122
[5] BRAF V600E confers resistance to cetuximab or panitumumab metastatic colorectal cancer
Di Nicolantonio, F.
Martini, M.
Molinari, F.
Bianchi, A. Sartore
Arena, S.
Saletti, P.
Mazzucchelli, L.
Frattini, M.
Siena, S.
Bardelli, A.
EJC SUPPLEMENTS, 2008, 6 (12): : 81 - 81
[6] Targeting CDK1/2-driven mechanisms of resistance to BRAF and EGFR inhibition in BRAF(V600E) colorectal cancer restores therapeutic response
Coppe, Jean-Philippe
Munoz, Denise P.
Atreya, Chloe E.
Hwang, Yeonjoo
Bouhaddou, Mehdi
Heinrich, Louise E.
Naser, Mohammad
Zakraoui, Ons
Pirker, Roxana
Guha, Rupa
Moelders, Christina
Scapozza, Alessandro
Schwarzer, Cecilia
Phillips, Layla
Wang, Changjun
van 't Veer, Laura
Steri, Veronica
VandenBerg, Scott R.
CANCER RESEARCH, 2024, 84 (06)
[7] The Targeted Degradation of BRAF V600E Reveals the Mechanisms of Resistance to BRAF-Targeted Treatments in Colorectal Cancer Cells
Chapdelaine, Abygail G.
Ku, Geng Chia
Sun, Gongqin
Ayrapetov, Marina K.
Roche, Serge
CANCERS, 2023, 15 (24)
[8] The prognostic value of systemic inflammatory factors in BRAF (V600E) mutant metastatic colorectal cancer (mCRC).
Martinez Lago, Nieves
Covela Rua, Marta
Brozos Vazquez, Elena
Fernandez Montes, Ana Fernandez
De la Camara Gomez, Juan Cruz
Mendez Mendez, Carlos
Jorge Fernandez, Monica
Cousillas Castineira, Antia
Grana Suarez, Begona
Quintero Aldana, Guillermo Alfonso
Candamio Folgar, Sonia
Salgado Fernandez, Mercedes
Pellon Augusto, Maria Luz
Gonzalez Villarroel, Paula
Gallardo Martin, Elena
Carmona Campos, Marta
Vazquez Rivera, Francisca
Grande Ventura, Carlos
Carral Maseda, Alberto
Reboredo Lopez, Margarita
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
[9] Acquired resistance to BRAF inhibitors is mediated by BRAF splicing variants in BRAF V600E mutation-positive colorectal neuroendocrine carcinoma
Shimizu, Yuki
Maruyama, Kohei
Suzuki, Mai
Kawachi, Hiroshi
Low, Siew-Kee
Oh-hara, Tomoko
Takeuchi, Kengo
Fujita, Naoya
Nagayama, Satoshi
Katayama, Ryohei
CANCER LETTERS, 2022, 543
[10] BRAF V600E and SRC mutations as molecular markers for predicting prognosis and conversion surgery in Stage IV colorectal cancer
Yoshifumi Shimada
Yusuke Muneoka
Masayuki Nagahashi
Hiroshi Ichikawa
Yosuke Tajima
Yuki Hirose
Takuya Ando
Masato Nakano
Jun Sakata
Hitoshi Kameyama
Yasumasa Takii
Yiwei Ling
Shujiro Okuda
Kazuaki Takabe
Toshifumi Wakai
Scientific Reports, 9

← 1 2 3 4 →